Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Humana Inc. pages available for free this week:
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Dividend Discount Model (DDM)
- Selected Financial Data since 2005
- Net Profit Margin since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Humana Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
- Operating Profit Margin
- The operating profit margin exhibited a peak in the third quarter of 2020 at 7.77%, followed by a general downward trend. While there was a moderate recovery in late 2022 and early 2023 with margins rising slightly above 4%, the metric has been declining steadily since, reaching 2.42% by the third quarter of 2024. This indicates a gradual reduction in operating efficiency or increased costs relative to revenues over the analyzed period.
- Net Profit Margin
- The net profit margin followed a similar trajectory to the operating profit margin. It peaked during the third quarter of 2020 at 5.67% and then decreased, experiencing minor fluctuations without significant rebound. The margin fell below 3% from the last quarter of 2022 onward, culminating at 1.19% in the third quarter of 2024. This trend reflects diminishing profitability after all expenses and taxes, highlighting increasing pressure on the company's bottom line.
- Return on Equity (ROE)
- Return on equity showed strong performance in the first three quarters of 2020, reaching a high of 26.34%, but experienced a noticeable decline in 2021. While some recovery occurred towards the end of 2022 and early 2023, ROE trended downward again from mid-2023 through 2024, falling to 7.74% by the third quarter of 2024. This suggests a decline in the company's ability to generate profits from equity capital invested by shareholders.
- Return on Assets (ROA)
- The return on assets peaked at 10.79% in the third quarter of 2020, followed by a general decline. It stabilized somewhat around 5-6% through 2022 and early 2023 but faced a further downward trend into 2024, reaching 2.72% by the third quarter of 2024. This indicates decreasing efficiency in utilizing assets to generate earnings over the observed timeframe.
- Summary of Trends
- All four key profitability and efficiency ratios reached their highest points in or around the third quarter of 2020, followed by a consistent decline or volatility with a downward bias up to the third quarter of 2024. This pattern may reflect increased operational challenges, cost pressures, or market conditions impacting profitability and asset utilization. The recent sharp decreases, particularly in 2024, warrant attention as they might indicate structural changes affecting financial performance.
Return on Sales
Return on Investment
Operating Profit Margin
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Income from operations | |||||||||||||||||||||||||
| External revenues | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q3 2024 Calculation
Operating profit margin = 100
× (Income from operationsQ3 2024
+ Income from operationsQ2 2024
+ Income from operationsQ1 2024
+ Income from operationsQ4 2023)
÷ (External revenuesQ3 2024
+ External revenuesQ2 2024
+ External revenuesQ1 2024
+ External revenuesQ4 2023)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial performance demonstrates fluctuating trends over the periods analyzed. Income from operations shows significant volatility, with notable negative values recorded at the end of 2020 and again in the last quarter of 2023. Despite occasional downturns, the company maintains positive operational income in most quarters, though the magnitude varies considerably.
External revenues exhibit a consistent upward trajectory throughout the entire timeline. The revenue growth is steady, indicating increasing sales or service income without evident seasonal or cyclical downturns. This gradual increase suggests strengthening market presence or successful business expansion strategies.
Operating profit margin percentages reflect a declining trend in profitability over time. The margin peaked around the third quarter of 2020, followed by a gradual reduction, reaching the lowest points in the final periods observed. This decline in operating efficiency may be attributable to rising costs, pricing pressures, or changes in the business mix that adversely affect profitability despite increasing revenues.
- Income from operations
- Demonstrates considerable fluctuations with intermittent negative results, indicating periods of operational challenges.
- External revenues
- Shows a sustained increase over the periods, signaling growth in business volume or market expansion.
- Operating profit margin
- Exhibits a decreasing pattern, implying reduced profitability and potential margin compression despite revenue gains.
Net Profit Margin
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net income attributable to Humana | |||||||||||||||||||||||||
| External revenues | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q3 2024 Calculation
Net profit margin = 100
× (Net income attributable to HumanaQ3 2024
+ Net income attributable to HumanaQ2 2024
+ Net income attributable to HumanaQ1 2024
+ Net income attributable to HumanaQ4 2023)
÷ (External revenuesQ3 2024
+ External revenuesQ2 2024
+ External revenuesQ1 2024
+ External revenuesQ4 2023)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Net Income Attributable to Humana
- The net income exhibits significant volatility throughout the periods. Starting with a notable increase from 473 million to 1,828 million US dollars in the first two quarters of 2020, the figure shows pronounced fluctuations thereafter, including several quarters with negative net income values (notably in December 2020, December 2021, December 2022, and December 2023). While the income rebounded strongly in certain quarters, such as March 2021 and March 2023, the overall trend in recent periods suggests a declining trajectory, with net income decreasing from 741 million in March 2024 to 480 million in September 2024.
- External Revenues
- External revenues have generally shown an upward trend over the examined timeline. From approximately 18.8 billion US dollars in early 2020, revenues increased steadily, reaching a peak of 29.3 billion US dollars in March 2024. Despite some minor quarter-to-quarter fluctuations, the growth in external revenues appears robust and consistent. The increases reflect positive top-line momentum, although the rate of growth slightly moderates in the latest quarters, with revenues stabilizing around the 29 billion mark.
- Net Profit Margin
- The net profit margin has demonstrated a declining trend over the period analyzed. Starting around 3.89% at the end of Q1 2020, margins peaked near 5.67% in Q3 2020 before beginning a downward path. Modest fluctuations occurred throughout 2021 and 2022, with margins hovering between 3% and 3.5%. However, from 2023 onwards, the margin contracted significantly, falling to just 1.19% by Q3 2024. This decreasing margin trend suggests increasing cost pressures or other operational challenges impacting profitability despite rising revenues.
- Overall Analysis
- The financial data reveals an organization experiencing substantial revenue growth but facing challenges in translating this growth into stable and increasing net income and profitability. The fluctuations in net income, including several negative quarters, along with the steady decline in net profit margin, raise concerns about cost management, expense structure, or external factors affecting financial performance. Maintaining revenue growth while addressing profitability issues will be critical for future financial stability and investor confidence.
Return on Equity (ROE)
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net income attributable to Humana | |||||||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROE1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q3 2024 Calculation
ROE = 100
× (Net income attributable to HumanaQ3 2024
+ Net income attributable to HumanaQ2 2024
+ Net income attributable to HumanaQ1 2024
+ Net income attributable to HumanaQ4 2023)
÷ Stockholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Income Trend
- The net income attributable shows significant volatility across the quarters. It peaked notably at 1,828 million USD in June 2020 and again reached highs above 1,500 million USD in the latter quarters of 2020 and 2021. However, several quarters recorded negative values, particularly in December 2020, December 2021, and December 2022, indicating periods of loss. The first quarter of 2024 reported a positive net income of 741 million USD, yet this declined in subsequent quarters, dipping to 480 million USD by September 2024. Overall, fluctuations suggest cyclical performance with intermittent losses impacting the income trajectory.
- Stockholders' Equity Trend
- Stockholders’ equity demonstrated a general upward trajectory over the period evaluated. Starting from 12,355 million USD at the end of March 2020, it rose steadily with minor dips, reaching 17,565 million USD by the third quarter of 2024. Although some quarters reflected slight declines, such as December 2020 and December 2022, the overall trend suggests an accumulation of shareholder value and retained earnings over time.
- Return on Equity (ROE) Analysis
- The Return on Equity exhibited a declining pattern over the analyzed timeframe. Initially, ROE was robust, exceeding 20% and peaking above 26% in the latter part of 2020 and early 2021. However, from late 2021 onwards, a gradual decline is observable, with ROE decreasing from levels around 18-20% down to a low of 7.74% by September 2024. This downward trend indicates diminishing profitability relative to shareholder equity, which may reflect earnings volatility or changes in operational efficiency.
- Overall Insights
- The company experienced fluctuating profitability with periods of strong net income as well as significant quarterly losses. While shareholder equity increased steadily, signaling strengthened balance sheet capacity, the declining ROE raises concerns about the efficiency in generating profits from equity. The mixed net income results combined with a gradually decreasing ROE suggest a need for close monitoring of operational performance and strategic initiatives to improve profitability going forward.
Return on Assets (ROA)
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net income attributable to Humana | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROA1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q3 2024 Calculation
ROA = 100
× (Net income attributable to HumanaQ3 2024
+ Net income attributable to HumanaQ2 2024
+ Net income attributable to HumanaQ1 2024
+ Net income attributable to HumanaQ4 2023)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial performance and position over the quarterly periods show notable fluctuations in net income, total assets, and return on assets (ROA). The net income attributable demonstrates significant volatility, with several quarters showing negative values, particularly at the end of 2020 and in late 2021, as well as in 2022 and 2023. Despite this, there are periods of strong positive net income, particularly in mid to late 2020 and early 2021, indicating an inconsistent earnings trend.
Total assets generally trend upward over the periods under review, with brief declines and fluctuations. Initial quarters show assets around the mid-30,000s in millions of US dollars, escalating and peaking in the range of 56,000 million in mid-2023 before experiencing a subsequent reduction, stabilizing around the 50,000 million mark in early 2024. This overall expansion in asset base suggests ongoing investment or growth initiatives, tempered by periods of consolidation or asset revaluation.
The return on assets (ROA) percentage reveals a declining trajectory over the timeline. Starting from relatively high levels above 7% and peaking near 11% in late 2020, the ROA decreases steadily to under 3% by the most recent quarters in 2024. This trend signals reduced efficiency in generating net income from asset investments, possibly reflecting the volatility in net income and the increasing total asset base which is not translating proportionally into earnings.
- Net Income Trends
- Exhibits high volatility with pronounced peaks and troughs; positive earnings are interspersed with several negative quarters, indicating fluctuations in operational profitability or extraordinary impacts affecting net results.
- Total Assets Movement
- Shows an overall growth pattern with occasional declines; the asset base expands significantly through 2023 followed by a slight contraction and stability in early 2024, suggesting active asset management.
- Return on Assets (ROA)
- Declining trend over time points to decreasing asset utilization efficiency; the index falls from double-digit percentages to below 3%, underlining challenges in maintaining profitability relative to asset size.